

MEDIA RELEASE

For immediate release

ACROMECC's Strategic Expansion into the Pharmaceutical Industry Yields Another Project Worth S\$7.5 Million from an Internationally Renowned Biopharmaceutical MNC

- S\$7.5 million contract from an internationally renowned biopharmaceutical MNC to construct an integrated laboratory facility which meets highly stringent industry standards.
- Contract win further strengthened our position in the growing pharmaceutical industry.
- Builds on track record for projects high in specifications and value, to maintain competitive edge.

SINGAPORE, 29 November 2017 - ACROMECC Limited ("**ACROMECC**", or the "**Company**" and together with its subsidiaries, the "**Group**"), an established specialist engineering service provider in the field of controlled environments serving mainly the healthcare, biomedical, pharmaceutical, research and academia, and electronics sectors, has secured a S\$7.5 million contract to construct an integrated laboratory facility involving the consolidation of various existing laboratories and a new laboratory which meets highly stringent industry standards (the "**Contract**") for a well-known biopharmaceutical multinational corporation (the "**MNC**"). This facility is located on the fourth floor of a green mark platinum-rated building at Science Park, Singapore, with a gross floor area of approximately 3,100 square metres.

The Contract was secured after stringent vetting by our client, to ensure that ACROMECC's project bid specifications meet the highly stringent pharmaceutical industry standards for its processes. The project is expected to be completed by 30 April 2018.

Commenting on the award of the Contract, Mr Lim Say Chin, the Executive Chairman and Managing Director of ACROMECC said, "*Our current strategy to prioritise and re-allocate a greater proportion of our resources, including manpower and business development capabilities, to such high-value projects has paid off. Barring unforeseen circumstances, we expect the pharmaceutical industry to grow considerably, not only in Singapore but also in the region, in time to come. We are therefore glad to be part of this growth.*" Mr Lim added that the encouraging outlook for the pharmaceutical industry is due to the region's strong economic growth, its demographic trends and local government policies that support the expected growth of the industry.

This award is also a continued testament of ACROMECC's track record as a provider of specialist engineering services, which it has successfully built over the years. The Contract marks the Group's expansion into the growing pharmaceutical industry. The Group believes that this high-specifications and high-value project will enable ACROMECC to maintain its competitive edge.

With this Contract, ACROMECC's order book stands at approximately S\$21 million.

The Contract is expected to contribute positively to the earnings per share and net tangible assets per share of the Group for the financial year ending 30 September 2018.

None of the Directors of the Company has any interest, direct or indirect, in the Contract, other than through their respective shareholdings in the Company. To the best of the Directors' knowledge, none of the controlling shareholders of the Company has any interests, direct or indirect, in the Contract, other than through their respective shareholdings in the Company.

-- End --

About ACROMECC Limited (SGX Stock Code: 1CH1)

ACROMECC is an established specialist engineering services provider with 20 years of experience in the field of controlled environments. The Group has over the years acquired expertise in the design and construction of facilities requiring controlled environments such as laboratories, medical and sterile facilities and cleanrooms.

ACROMECC's business is divided into two main business segments: (i) Engineering, procurement and construction services, specialising in architectural, and mechanical, electrical and process works within controlled environments; and (ii) Maintenance and repair services of facilities and equipment of controlled environments and their supporting infrastructure.

The Group mainly serves the healthcare, biomedical, pharmaceutical, research and academia, and electronics sectors. ACROMECC counts amongst its customers, hospitals and medical centres, government agencies, research and development companies or agencies, research and development units of multinational corporations, tertiary educational institutions, pharmaceutical companies, semiconductor manufacturing companies, and multinational engineering companies. For more information, please visit www.acromec.com.

Media and Analysts Contact:

Acromec Limited

Mr Jerry Tan

Chief Financial Officer

Tel: +65 6415 0574

Email: jerry.tan@acromec.com

Waterbrooks Consultant Pte Ltd

Ng Tian Khean

Mobile: + 65 96402808

Email: tk@waterbrooks.com.sg

This media release has been prepared by ACROMEC and its contents have been reviewed by the Company's sponsor, SAC Capital Private Limited (the "Sponsor"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "SGX-ST"). The Sponsor has not independently verified the contents of this media release.

This media release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this media release, including the correctness of any of the statements or opinions made or reports contained in this media release.

The contact person for the Sponsor is Mr Ong Hwee Li (Telephone: +65 6532 3829) at 1 Robinson Road #21-02 AIA Tower, Singapore 048542.